Yasuteru Kondo

15PUBLICATIONS
46CO-AUTHORS
Traditional Chinese medicine and treatmentsPredictive and prognostic markersGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)Autonomic nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Feb 26, 2025
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.

Hideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo

|Feb 13, 2025
Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice.

Junji Furuse, Namiki Izumi, Kenta Motomura

|Jul 11, 2024
Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.

Hideaki Miyamoto, Yasuteru Kondo, Ei Itobayashi

|Mar 11, 2023
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga, Masakuni Tateyama, Yasuteru Kondo

|Mar 25, 2022
Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.

Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi

|Jun 09, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.

Kazuhiro Kozumi, Takahiro Kodama, Hiroki Murai

Pageof 3

Frequent Collaborators

3 joint publications

Yasuhito Tanaka

2 joint publications

Takumi Kawaguchi

2 joint publications

Yoshiyuki Ueno

2 joint publications

Yoji Ishizu